| Today's Big NewsOct 27, 2022 |
|
A GPS to your next blockbuster drug - Design molecules towards your desired properties through AI+Biophysics. Learn more. 
|
|
| By Zoey Becker In the latest tax avoidance investigation into a Big Pharma company, Italian finance authorities are probing Pfizer's Italian unit for allegedly offshoring profits of at least $1.2 billion, Bloomberg reports. |
|
|
|
By Nick Paul Taylor GSK has dumped one of its top pipeline prospects. While two of the three phase 3 trials of otilimab hit their primary endpoints, the Big Pharma concluded the efficacy fell short of the level needed to take the anti-GM-CSF antibody forward in rheumatoid arthritis. |
By Robert King CMS is cracking down on Medicare Advantage marketing practices, including implementing a new requirement next year for federal approval of an TV ads before they air. |
By Andrea Park If the last year has taught diagnostic developers anything, it’s not to underestimate what Abbott CEO Robert Ford recently termed the “stickiness” of COVID-19 tests—even as case rates remain well below their peaks and testing requirements relax. |
By Kevin Dunleavy A day after he was named Merck's next chairman, in addition to his CEO duties, Rob Davis touted his efforts to beef up the company's pipeline, citing a promising group of cardiovascular drugs. |
By Max Bayer Merck is dropping the cancer treatment acquired in its acquisition of Viralytics back in 2018. A spokesperson confirmed that the asset was axed as a part of the company's prioritization efforts. |
By Dave Muoio The acute and behavioral care company said its operations are still feeling the sting of COVID-19 and labor shortages. |
By Andrea Park Upping the rates of women who actually receive proper and effective treatments will start with practical changes at the clinical trial level, backed by an overhaul of traditional beliefs about who is represented in healthcare. |
By Angus Liu The readout for newly FDA-approved Amvuttra in ATTR cardiomyopathy is on many Alnylam investors’ mind. But the company figures patience is a virtue. It's also taking some time to consider another Amvuttra development plan, citing the Inflation Reduction Act. |
By Nick Paul Taylor Bristol Myers Squibb has inked a multi-year extension to its collaboration with Obsidian Therapeutics, securing itself the exclusive option to license cell therapies that use its partner’s technology to control the expression of CD40L. |
By Paige Minemyer Walmart Health is planning its next expansion. The retail giant said Wednesday that it will open an additional 16 health centers in Florida over the next year, focused in the Jacksonville, Orlando and Tampa markets. |
By Andrea Park In recent years, 23andMe has repositioned itself as a genetic testing company that does more than help users fill out their family trees, but also answer crucial questions about their predispositions for potential conditions. |
By Gabrielle Masson Bluebird spinout 2seventybio and China-based CAR-T company JW Therapeutics are joining forces to build out a cell therapy platform in hopes of creating T cell receptor therapies for certain solid tumors. |
Fierce podcasts Don't miss an episode |
| This week on "Podnosis," we talk about how MA plans are rethinking their sales pitch. We also eavesdrop on a panel discussion at the Fierce Health Payer summit on how payers are looking to address social determinants of health. |
|
|---|
|
|
|
Tuesday, November 15, 2022 | 1pm ET / 10am PT In this webinar, learn how Medable is focused on improving access to clinical trials for patients, supporting the innovation of clinical trial delivery and offering greater choices for participation and engagement to patients. Register now.
|
|
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Whitepaper Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
eBook Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
